A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)

Purpose To establish the recommended phase II dose of the oral γ-secretase inhibitor RO4929097 (RO) in combination with gemcitabine; secondary objectives include the evaluation of safety, tolerability, pharmacokinetics, biomarkers of Notch signaling and preliminary anti-tumor activity. Methods Patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Suzanne, Bedard, Philippe L., Chen, Eric Xueyu, Clarke, Blaise A., Tran, Ben, Hotte, Sebastien J., Stathis, Anastasios, Hirte, Hal W., Razak, Albiruni R. A., Reedijk, Michael, Chen, Zhuo, Cohen, Brenda, Zhang, Wen-Jiang, Wang, Lisa, Ivy, S. Percy, Moore, Malcolm J., Oza, Amit M., Siu, Lillian L., McWhirter, Elaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869895/
https://www.ncbi.nlm.nih.gov/pubmed/23645447
http://dx.doi.org/10.1007/s10637-013-9965-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869895/
https://www.ncbi.nlm.nih.gov/pubmed/23645447
http://dx.doi.org/10.1007/s10637-013-9965-4

Ejemplares similares